Ruxolitinib for Steroid-refractory GVHD

Status Completed

Clinical Trial Summary

Steroid-refractory acute GVHD (srGVHD) is one of the causes of mortality after allogeneic stem cell transplantation, while steroid-refractory chronic GVHD significantly increases morbidity, aggravates quality of life and may also impact survival. Currently there is no standard treatment of srGVHD. One of the most promising agents is Janus kinase (JAK) inhibitor ruxolitinib, which in the retrospective study demonstrated excellent response rate and survival of patients with either acute or chronic srGVHD. This study prospectively evaluates the efficacy of ruxolitinib in srGVHD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Graft Vs Host Disease

Clinical Trial Details

NCT number	NCT02997280
Study type	Interventional
Source	St. Petersburg State Pavlov Medical University
Contact
Status	Completed
Phase	Phase 2
Start date	August 2016
Completion date	April 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06080490` - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed	`NCT00001637` - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults	Phase 2
Withdrawn	`NCT04728646` - Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes	Phase 4
Suspended	`NCT01972438` - A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients	Phase 1/Phase 2
Completed	`NCT01221766` - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease	N/A
Recruiting	`NCT01764100` - Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)	Phase 1
Completed	`NCT00760981` - A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease	Phase 1
Terminated	`NCT00298324` - Myfortic - Treatment for Extensive cGvHD	Phase 3
Completed	`NCT00224874` - Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)	Phase 2
Completed	`NCT00023491` - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells	N/A
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Recruiting	`NCT05111834` - IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms	N/A
Completed	`NCT02841995` - A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease	Phase 2
Recruiting	`NCT06143501` - Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
Recruiting	`NCT04622956` - GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide	Phase 1/Phase 2
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Recruiting	`NCT03836690` - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation	Phase 1
Not yet recruiting	`NCT02506231` - The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome	Phase 2/Phase 3
Recruiting	`NCT01042509` - Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease	N/A
Terminated	`NCT00117702` - Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus	Phase 2/Phase 3